Ken Griffin’s BioAge Labs BIOA Stock Holding History

Ken Griffin’s Portfolio BIOA Stock Details BIOA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,100	Closed	-$65.3K	–	14362
2025 Q3	$65.3K	Buy	+11,100	New	+$52K	﹤0.01%	12068

Other funds holding BIOA

ACM

AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Ken Griffin's BIOA Position: Q1 2026 in Review

Ken Griffin sold out of BioAge Labs (BIOA) in Q1 2026, closing a stake of 230,543 shares — an estimated $4.44M sold.

Ken Griffin first reported a position in BIOA in Q3 2024 and held it in 4 quarters. The position peaked at $4.45M in Q3 2024. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

Ken Griffin reported no remaining BioAge Labs position as of Q1 2026 after selling out during the quarter.
Ken Griffin sold 230,543 BioAge Labs shares in Q1 2026, an estimated $4.44M.
Ken Griffin first reported a position in BioAge Labs in Q3 2024 and held it in 4 quarters.
Ken Griffin's BioAge Labs position peaked at $4.45M in Q3 2024.
144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.